Michael L. Vetter, PhD

Dr. Michael Vetter represents biotechnology companies and research institutions, helping them to protect complex business-critical intellectual property and providing guidance for U.S. and international patent prosecution of portfolios for a range of enterprises, including academic research centers, start-ups, and established biotech and pharmaceutical companies. Michael draws upon this robust technical background to deliver sophisticated counsel which combines a detailed knowledge of clients’ technologies with a strategic understanding of their business goals. Michael also helps clients in Choate’s Healthcare Group to assess potential data manipulation or fabrication – scientific misconduct – for academic medical centers and private biotechnology companies.

Industry Experience

As a Research Fellow at Harvard Medical School, Michael examined host-viral pathogen interaction, with a focus on understanding the role of several different kinases in early post-entry and egress events of Dengue virus, and was the recipient of the Virus-Host Interactions and Cancer Training Grant. Michael completed his PhD studies at Vanderbilt University, where his research focused on investigating the effect of CD4+ T cell differentiation on the expression of the HIV restriction factor APOBEC3. While at Vanderbilt, Michael received the Cellular and Molecular Microbiology Training Grant, as well as the Conference on Retroviruses and Opportunistic Infections Young Investigator Award. Prior to obtaining his PhD, Michael was a Research Assistant at the Case Western Reserve University School of Medicine’s Division of Hypertension, where he investigated signaling of the second messenger cGMP.

Representative Engagements

  • Adimab, LLC v. LinkedUp Bioscience, Inc. and Tao Wang, No., Mass. Super. Ct: Counsel to Adimab in trade secret misappropriation and breach of contract dispute brought against LinkedUp related to highly engineered yeast strains, and technologies for cultivating and utilizing those strains to express and screen antibodies that bind to target antigens.

Publications and Presentations

  • “Fluorescent Visualization of Src by Using Dasatinib-BODIPY,” first author, ChemBioChem.
  • “Chemoproteomic Profiling Identifies Changes in DNA-PK as Markers of Early Dengue Virus Infection,” first author, ACS Chemical Biology, cover article.
  • “Cytoplasmic APOBEC3G in Activated T Helper Subtype Cells Restricts Incoming Vif-positive HIV-1,” first author, Journal of Virology.
  • “Differences in APOBEC3G Expression in CD4+ T Helper Lymphocyte Subtypes Modulate HIV-1 Infectivity,” first author, PLOS Pathogens.
  • “Cyclosporin A Disrupts Bradykinin Signaling Through Superoxide,” first author, Hypertension.

Professional and Community Involvement

  • As a PhD student, Michael served as an AIDS Outreach Coordinator in Nashville, where he organized and trained volunteers to educate students about HIV and AIDS and participated as a volunteer educator at local schools and in national video conferences

Education & Credentials

Suffolk University Law School
JD, 2020
Vanderbilt University
PhD, 2009, Microbiology and Immunology
Case Western Reserve University
BA, 1999, Biology